These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33741643)

  • 1. Dose-Response and Dose-Toxicity Relationships for Glass
    Alsultan AA; van Roekel C; Barentsz MW; Smits MLJ; Kunnen B; Koopman M; Braat AJAT; Bruijnen RCG; de Keizer B; Lam MGEH
    J Nucl Med; 2021 Nov; 62(11):1616-1623. PubMed ID: 33741643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.
    van den Hoven AF; Rosenbaum CE; Elias SG; de Jong HW; Koopman M; Verkooijen HM; Alavi A; van den Bosch MA; Lam MG
    J Nucl Med; 2016 Jul; 57(7):1014-9. PubMed ID: 26912436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-Effect Relationships of
    van Roekel C; Bastiaannet R; Smits MLJ; Bruijnen RC; Braat AJAT; de Jong HWAM; Elias SG; Lam MGEH
    J Nucl Med; 2021 Feb; 62(2):272-279. PubMed ID: 32591491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma.
    Wagemans MEHM; Kunnen B; Stella M; van Rooij R; Smits M; Bruijnen R; Lam MGEH; de Jong HWAM; Braat AJAT
    J Nucl Med; 2024 Feb; 65(2):272-278. PubMed ID: 38176716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases.
    Ebbers SC; van Roekel C; Braat MNGJA; Barentsz MW; Lam MGEH; Braat AJAT
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1700-1710. PubMed ID: 34873638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.
    Hickey R; Lewandowski RJ; Prudhomme T; Ehrenwald E; Baigorri B; Critchfield J; Kallini J; Gabr A; Gorodetski B; Geschwind JF; Abbott A; Shridhar R; White SB; Rilling WS; Boyer B; Kauffman S; Kwan S; Padia SA; Gates VL; Mulcahy M; Kircher S; Nimeiri H; Benson AB; Salem R
    J Nucl Med; 2016 May; 57(5):665-71. PubMed ID: 26635340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First Evidence for a Dose-Response Relationship in Patients Treated with
    Bastiaannet R; van Roekel C; Smits MLJ; Elias SG; van Amsterdam WAC; Doan D; Prince JF; Bruijnen RCG; de Jong HWAM; Lam MGEH
    J Nucl Med; 2020 Apr; 61(4):608-612. PubMed ID: 31601696
    [No Abstract]   [Full Text] [Related]  

  • 8. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
    Flamen P; Vanderlinden B; Delatte P; Ghanem G; Ameye L; Van Den Eynde M; Hendlisz A
    Phys Med Biol; 2008 Nov; 53(22):6591-603. PubMed ID: 18978442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High quality imaging and dosimetry for yttrium-90 (
    Duan H; Khalaf MH; Ferri V; Baratto L; Srinivas SM; Sze DY; Iagaru A
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2426-2436. PubMed ID: 33443618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioembolization with
    Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT.
    Chansanti O; Jahangiri Y; Matsui Y; Adachi A; Geeratikun Y; Kaufman JA; Kolbeck KJ; Stevens JS; Farsad K
    J Vasc Interv Radiol; 2017 Nov; 28(11):1528-1535. PubMed ID: 28888827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioembolization of hepatocarcinoma with
    Chiesa C; Mira M; Bhoori S; Bormolini G; Maccauro M; Spreafico C; Cascella T; Cavallo A; De Nile MC; Mazzaglia S; Capozza A; Tagliabue G; Brusa A; Marchianò A; Seregni E; Mazzaferro V
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3018-3032. PubMed ID: 32451604
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Tabotta F; Gnesin S; Dunet V; Ponti A; Digklia A; Boughdad S; Schaefer N; Prior JO; Villard N; Tsoumakidou G; Denys A; Duran R
    Sci Rep; 2023 Aug; 13(1):13118. PubMed ID: 37573346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
    Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
    Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Tumor Control in
    Dewaraja YK; Devasia T; Kaza RK; Mikell JK; Owen D; Roberson PL; Schipper MJ
    J Nucl Med; 2020 Jan; 61(1):104-111. PubMed ID: 31147404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular Carcinoma Tumor Dose Response After
    Kappadath SC; Mikell J; Balagopal A; Baladandayuthapani V; Kaseb A; Mahvash A
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):451-461. PubMed ID: 30191875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
    Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
    J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-effect relationships in neuroendocrine tumour liver metastases treated with [
    Ramdhani K; Beijer-Verduin J; Ebbers SC; van Rooij R; Smits MLJ; Bruijnen RCG; de Jong HWAM; Lam MGEH; Braat AJAT
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2114-2123. PubMed ID: 38369678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.